MaxCyte, Inc.

NasdaqGS MXCT

MaxCyte, Inc. Market Capitalization on February 06, 2025: USD 472.56 M

MaxCyte, Inc. Market Capitalization is USD 472.56 M on February 06, 2025, a -8.42% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

MaxCyte, Inc. 52-week high Market Capitalization is USD 539.17 M on January 21, 2025, which is 14.09% above the current Market Capitalization.
MaxCyte, Inc. 52-week low Market Capitalization is USD 340.71 M on November 18, 2024, which is -27.90% below the current Market Capitalization.
MaxCyte, Inc. average Market Capitalization for the last 52 weeks is USD 440.62 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: MXCT

MaxCyte, Inc.

CEO	Mr. Maher Masoud
IPO Date	July 30, 2021
Location	United States
Headquarters	9713 Key West Avenue
Employees	143
Sector	Healthcare
Industries Biotechnology 3D Printing

Description

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Key trends

Past 5 years